ID   JHU-011
AC   CVCL_5986
SY   JHU 011; JHU-011-SCC; JHU-O11; JHU011; HNSCC 011; O11; 011; 11; Johns Hopkins University-011
DR   BTO; BTO:0003891
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2719
DR   BioGRID_ORCS_Cell_line; 905
DR   BioSample; SAMN03471775
DR   cancercelllines; CVCL_5986
DR   Cell_Model_Passport; SIDM00128
DR   Cosmic-CLP; 1240161
DR   DepMap; ACH-002249
DR   EGA; EGAS00001000978
DR   GDSC; 1240161
DR   GEO; GSM1669958
DR   PharmacoDB; JHU011_692_2019
DR   PRIDE; PXD002132
DR   PRIDE; PXD030304
DR   Wikidata; Q54898667
RX   PubMed=12925955;
RX   PubMed=12963126;
RX   PubMed=21868764;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29156801;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.03%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=0.29%; European, North=66.03%; European, South=29.59% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-2719; true.
CC   Derived from site: In situ; Larynx; UBERON=UBERON_0001737.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9,14
ST   D5S818: 9,12
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 16,17
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 26
//
RX   PubMed=12925955; DOI=10.1002/ijc.11341;
RA   Minhas K.M., Singh B., Jiang W.-W., Sidransky D., Califano J.A. III;
RT   "Spindle assembly checkpoint defects and chromosomal instability in
RT   head and neck squamous cell carcinoma.";
RL   Int. J. Cancer 107:46-52(2003).
//
RX   PubMed=12963126; DOI=10.1016/S0304-3835(03)00344-6;
RA   Hoque M.O., Begum S., Sommer M., Lee T., Trink B., Ratovitski E.,
RA   Sidransky D.;
RT   "PUMA in head and neck cancer.";
RL   Cancer Lett. 199:75-81(2003).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//